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The hypothesis that epithelial–mesenchymal transition (EMT)
might be a contributor to the accumulation of fibroblasts and
myofibroblasts (MFs) in the kidney during fibrogenesis was
postulated 15 years ago. This paradigm offered an elegant
explanation of how the loss of epithelial functions is coupled
to the gain of deleterious mesenchymal functions; for
example, excessive matrix deposition. Moreover, it
interpreted chronic kidney disease in a developmental
context: because the tubular epithelium originates from the
metanephric mesenchyme, EMT can be viewed as a
dedifferentiation process in response to injury, which might
serve healing or—if dysregulated—might facilitate fibrosis.
Several observations support the role of EMT in renal fibrosis:
(1) Tubular cells can transform to fibroblasts and MFs in vitro.
(2) Histological ‘snapshots’ reveal the coexistence of
epithelial and mesenchymal markers in transitioning tubular
cells in fibrosis models and human kidney diseases. (3) Early
lineage-tracing experiments detected mesenchymal markers
in the genetically tagged epithelium. However, the paradigm
has been recently challenged; new fate-mapping studies
found no evidence for the expression of (myo)fibroblast
markers in the epithelium during fibrogenesis. This review
summarizes the key findings and caveats, aiming at a
balanced view, which neither overestimates the role of the
epithelium in MF generation nor denies the importance of
epithelial plasticity in fibrogenesis.
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PRELUDE: ORGAN FIBROSIS—THE COMPLEX CELL BIOLOGY
OF A MAJOR CLINICAL PROBLEM
In his thought-provoking review,1 Thomas Winn called the
world’s attention to the underappreciated fact that E45% of
all deaths in the western world can be attributed to some form
of tissue or organ fibrosis. Kidney diseases signify an
important set within this category, as essentially all chronic
nephropathies, irrespective of their etiology, culminate in a
final common pathological pathway characterized by glomer-
ulosclerosis and/or tubulointerstitial fibrosis.2,3 Organ fibrosis
is generally viewed as a dysregulated (and thus failed) healing
process provoked by chronic or repetitive injury of the
epithelium or endothelium of the affected parenchymal
organs.4 The key feature of the process is the tissue
accumulation of fibroblasts and their contractile and poten-
tially invasive subtype, the myofibroblasts (MFs), hallmarked
by the expression of a-smooth muscle actin (SMA). These
cell types, stimulated by a variety of fibrogenic cytokines
(predominantly by transforming growth factor-b1,5 and other
humoral and mechanical inputs emanating from the injured
environment6–8 lay down an excessive amount of extracellular
matrix (ECM), which ultimately leads to the destruction of
the normal tissue architecture. In short, the epithelium is
gradually replaced by mesenchymal cells and fibrous scar
tissue. Given this scenario, it is understandable that the
question of where the accumulating fibroblasts (and MFs)
originate from has become a major focus in fibrosis research.
Although this problem is not yet resolved, evidence has been
accumulating that the sources are multiple and, depending on
the organ (for example, lung, liver, lens, or kidney) and the
underlying pathology, both proliferation and transformation
of local cells, as well as population of the affected organ by
external fibroblast progenitors may contribute to the process.9
Accordingly, the sources may include local interstitial
fibroblasts,10 pericytes (or perivascular fibroblasts),11,12 local
mesenchymal stem cells, bone marrow-derived-circulating
fibrocytes13 (Cd45 and collagen-1-positive cells), the endothe-
lium,14,15 and last but not least, the injured epithelium
itself 16,17 In this short overview, we will concentrate on the latter
mechanism, that is, on the concept that during fibrogenesis,
fibroblasts can be generated from the epithelium through the
process of epithelial–mesenchymal transition (EMT).
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THE BIRTH OF A PARADIGM
In 1995, aiming at finding distinguishing markers for
fibroblasts, Strutz et al.18 used subtractive hybridization
between murine fibroblasts and isogenic epithelium, and
identified fibroblast-specific protein 1 (FSP1, also called
S1004A) as one of the few gene products that was expressed
in fibroblasts but not in mesangial or epithelial cells.
Generation of an anti-FSP1 serum provided a powerful tool
to address the origins of fibroblasts in fibrosing tissues. Using
this reagent, and thereby discovering that a portion of tubular
cells became FSP1 positive during immune-induced fibro-
genesis, the Neilson group made an extremely careful (and
pioneering) assumption: ‘This pattern of anti-FSP1 staining
during tissue fibrosis suggests, as a hypothesis, that
fibroblasts in some cases arise, as needed, from the local
conversion of epithelium’.18 This sentence signified the birth
of a new paradigm: the role of local EMT in fibrogenesis
(Figure 1). This concept is both powerful and intellectually
appealing for two major reasons. First, it offers a direct link
between the loss of epithelial functions (for example,
absorption and secretion) and the gain of deleterious
mesenchymal functions (enhanced ECM production). Sec-
ond, it roots in and is consistent with the developmental
biology of the kidney in that the tubular epithelium is a
secondary epithelium, which differentiates from the meta-
nephric mesenchyme through the process of mesenchy-
mal–epithelial transition.19 In this sense, the response to
epithelial injury could be interpreted as the activation of a
dedifferentiation program, which might either lead to healing
through an epithelial–mesenchymal–epithelial cycle20 or it
might result in fibrosis through EMT.21
SUPPORTING FINDINGS AND EMERGING CHALLENGES
Prompted by this exciting intellectual framework, a large
number of researchers set to work to establish the potential
role of EMT in fibrogenesis. In the past 15 years, several
hundred papers have been published, which provided
observational and experimental support for the possibility
that EMT is a contributor to organ fibrosis, in general, and
tubulointerstitial fibrosis, in particular. (For excellent reviews,
see refs 3,9,17,21–27.) These supportive arguments can be
broadly classified into four categories: (1) Demonstration
that tubular and other epithelial cells can indeed transform
into fibroblasts and MFs when cultured and challenged in
vitro. There is no doubt that epithelial cells possess this
potentiality as a part of their repertoire in response to injury.
(2)28–30 ‘Snapshots’ of molecular markers and events
characteristic of EMT, as detected in tubular cells in vivo,
during clinical or experimental fibrosis. These observations
can be divided into two sets. The first demonstrates
downregulation (partial loss) of epithelial markers (for
example, E-cadherin) and concomitant upregulation of
mesenchymal markers (for example, FSP1) in the injured
(transitioning) epithelium. The second documents changes
in the expression or activity of transcription factors,
reflecting a profound transcriptional reprogramming, which
is consistent with the reported transcriptional signature of
EMT (see next section). (3) Fate-mapping or lineage-tracing
experiments, in which the epithelium is genetically tagged,
and thus cells of epithelial origin can be identified
throughout the disease process. Using one version of this
approach (see below) Iwano et al.,16 concluded that 36% of
FSP1þ cells (that is, fibroblasts) originated from the
epithelium during unilateral ureteral obstruction (UUO) as
a model of kidney fibrosis. Qualitatively similar findings were
obtained in lung,31–33 liver,34 and intestinal models.35 (4)
Finally, recent data suggest that therapeutic approaches
targeted to suppress EMT may lessen fibrosis,36,37 and
conversely, antifibrotic interventions can mitigate the signs
of EMT.38–40
Although certainly compelling, the concept of fibrogenic
EMT has been recently challenged. Although the presence
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Figure 1 |The paradigm of tubular epithelial–mesenchymal
transition. According to this view, upon exposure to fibrogenic
stimuli (box in center), the tubular epithelium undergoes
profound phenotypic changes, which result in the loss of
epithelial features and functions and the gain of mesenchymal
characteristics. The transitioning cells might remain in the tubular
wall or might migrate into the interstitium. Epithelium-derived
fibroblasts contribute to the deposition of extracellular matrix
(ECM), and a subpopulation of them starts expressing a-smooth
muscle actin (SMA), the hallmark of the myofibroblast (MF)
phenotype. Activated fibroblasts and MF themselves secrete
elevated amounts of transforming growth factor-b (TGF-b),
whereas the enhanced contractility of MFs (further facilitated by
the ensuing tissue stiffness) contributes to the activation of latent
TGF-b through an integrin-mediated mechanochemical pathway.
The increasing TGF-b levels along with ECM accumulation
facilitate the transformation of previously intact tubules, thereby
creating a vicious circle (positive feedback) of epithelial injury.
Clearly, fibroblasts and MFs originate from a variety of other cell
types as well (bottom box), which may have major roles in the
process of fibrogenesis. AJ, adherens junction; EPI, epithelium;
FIBRO, fibroblast; TJ, tight junction.
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and role of EMT in lung fibrosis appear to be generally
accepted,41 doubts have been raised in the context of the
kidney12,42,43 and the liver44,45 on the basis of the results of
new fate-mapping experiments (Table 1). For example, using
different epithelial and mesenchymal tags (see below),
Humphreys et al.12 found no evidence of EMT during
UUO or ischemic injury, postulating that the epithelium did
not give rise to any SMAþ or even FSP1þ cells. Instead they
proposed that (myo)fibroblasts were exclusively derived from
local pericytes.
These opposite views have led to an ongoing debate. The
arguments for and against the presence and participation of
EMT have been eloquently summarized in a recent issue of
JASN46 by Michael Zeisberg and Jeremy Duffield, respec-
tively, two excellent representatives of each opinion, whose
studies had a major role in the very foundation of the
differing viewpoints. Our short summary cannot and does
not aspire to settle the debate or to take sides; its goal is to
highlight a few facts and considerations, which may help
to better define the fundamental concepts in question and to
point out the strengths, as well as the potential pitfalls and
limitations of each of the approaches used to address the
problem. Clearly, having a meaningful debate will depend
upon (1) the criteria that one uses to define EMT; (2) the
particular disease entity or experimental model in which
fibrosis and EMT are studied; and (3) the methods used to
Table 1 | Lineage tracing studies assessing the presence of EMT during fibrogenesis
Organ
cell type
Driver (Promoter)/
Reporter system Fate marker
Disease
model
Fibrosis
marker
Conclusion with regards
to EMT, remarks Ref
LUNG
Alveolar epithelium Surfactant (SCP)-rTA/
tetO-CMV-Cre
ROSA26LacZ
b-galactosidase /X-gal Ad-TGFb1- induced
pulmonary fibrosis
SMA, vimentin Yes 31
Alveolar epithelium Surfactant (SCP)-rTA/
tetO-CMV-Cre ZEG
GFP Bleomycin-induced
pulmonary fibrosis
SMA, vimentin,
procollagen I
Yes
Epithelial-specific deletion
of a3 integrin prevented
EMT
32
Alveolar epithelium SCP-Cre/ROSA26LacZ
S100A4-GFP
S1004A-Cre
b-galactosidase/anti-
b-gal AB GFP
Bleomycin-induced
pulmonary fibrosis
FSP1
SMA
GFP (SFP1 promoter)
Yes 33
KIDNEY
Tubular epithelium b-glutamyl transferase -
Cre/ROSA26LacZ
b-galactosidase/anti-
b-gal AB
UUO FSP1
HSP47
SMA
Yes 16
Tubular epithelium Six2-GFP-Cre/
ROSA26LacZ or Z/Red
(CMV/b-actin)
HoxB7-Cre/ROSA26LacZ
or Z/Red (CMV/b-actin)
b-galactosidase /X-gal
RFP
b-galactosidase/X-gal
RFP
UUO Ischemia-
reperfusion
SMA
FSP1
No
Mesenchymal cells were also
genetically tagged with
FOXD1
12
Tubular and ureteral
epithelium
Ksp-Cre/ROSA26-EYFP EYFP UUO E-cadherin
FSP1
SMA
No 42
Tubular epithelium Pax8rtTA/LC1/ROSA26R/
tet-o-TGF-b1
b-galactosidase/X-gal Tetracyclin-inducible
expression of active
TGFb in tubular cells
Directly: collagen I In
parallel but not with
labeled epithelium:
FSP1, SMA
No 43
LIVER
Hepatocytes Alb-Cre/ROSA26LacZ b-galactosidase/anti-
b-gal AB
CCL4-induced liver
fibrosis
E-cadherin
FSP1
SMA
Yes
Smad7 prevented EMT
34
Hepatocytes Alb-Cre/ ROSA26LacZ
a1(I) collagen promoter-
GFP
b-galactosidase/anti-
b-gal AB
CCL4-induced liver
fibrosis
SMA
FSP1
No collagen promoter was
not activated in
hepatocytes (GFP)
44
Cholangiocytes Cytokeratin 19-Cre-
ErtYFP/ROSA26YFP
YFP Bile duct ligation
CCL4-induced fibrosis
SMA
Desmin
FSP1
No
Potential activation of the
FSP1 promoter FSP1-Cre/
Rosa26/YFP was also tested.
MET was also assessed using
GFAP-Cre/Rosa26/GFP and
Col-a2(I)-YFP animals
45
GUT
Intestinal epithelium Villin-Cre/ ROSA26LacZ b-galactosidase/anti-b-
gal AB
2,4,6-trinitrobenzene
sulfonic acid (TNBS)-
induced colonic
inflammation (Crohn’s
disease)
E-cadherin FSP1 Yes 35
Fate-mapping studies have given discordant results about the presence of EMT in organ fibrosis. The discrepancies might be due to different methods to define and detect
EMT in various disease models. Systematic comparisons of such variables as well as the assessment of potential differences in the background strains (a factor not easily
determined in multiple transgenic animals) are warranted to establish the contribution of EMT to fibrogenesis. FSP1, fibroblast-specific protein 1; UUO, unilateral ureteral
obstruction.
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detect EMT. We hope that this overview will facilitate the
design of future studies and will contribute to the emergence
of a balanced view, which avoids both the overestimation of
the role of EMT in MF generation and the denial of the
presence and importance of epithelial plasticity during
fibrogenesis.
DEFINITION, TYPES MARKERS, AND CHARACTERISTICS OF
EMT: LESSONS LEARNED IN VITRO AND IN VIVO
EMT is defined as a phenotypic change, characterized by the
loss of apico-basal polarity, polygonal cell shape, and
epithelial intercellular contacts (tight and adherens junc-
tions), accompanied by the acquisition of elongated (mes-
enchymal) shape, increased motility, and contractility.24,47–49
The process involves dramatic remodeling of the cytoskele-
ton, which usually manifests as a cytokeratin-to-vimentin
switch in the intermediate filaments and restructuring of
microfilaments, with a loss of the junctional F-actin belt and
an increase in stress fibers and/or peripheral F-actin
branches. The basic theme of this profound form of epithelial
plasticity can be supplemented with other attributes, such as
excessive production of ECM, SMA expression, invasiveness,
and reduction in apoptosis. According to the biological
context in which EMT occurs as well as the presence of
some specific attributes, the International EMT Association
(TEMTIA) accepted the suggestion that EMT be classified
into three subtypes.23,25,50 Type 1 or developmental EMT
occurs during embryogenesis (for example, gastrulation or
neuronal crest cell formation), when primitive epithelial cells
give rise to the mesenchymal cells, which in turn generate the
mesendoderm. This process produces motile cells but does
not involve excessive ECM deposition or intravascular
invasion. During type 2 or fibrogenic EMT, secondary
epithelial cells morph into fibroblasts (epithelial–fibroblast
transition), which produce increased amount of ECM, and
may show muscle-like characteristics. Type 3 or metastasis-
associated EMT occurs when carcinoma cells turn into
migrating and invasive mesenchymal cells (carcinoma–meta-
static transition), which enter the bloodstream and form
distant metastases in which they may revert to cancerous
epithelial cells.
Type 2 EMT is associated with a plethora of changes in
protein expression,25 which predominantly affect the follow-
ing functional categories: (1) constituents of the intercellular
junctions, (2) molecules involved in cell–ECM interactions,
(3) cytoskeletal components, and (4) the corresponding
transcriptional regulators (Figure 2). The first set includes
loss of epithelial adherens junction component E-cadherin,
downregulation of tight junction constituents zonula
occludens-1, occludin and various claudins,28–30,51,52 and
upregulation of mesenchymal junctional proteins such as
N- or OB-cadherin.53,54 Changes related to ECM components
Cytokeratin
Intercellular contacts
Transcriptional regulators
Vimentin
ECM
FSP1
F-actin, SMA
Dissolution and downregulation of
epithelial intercellular contacts:
• E-cadherin
• Occludin
• Claudins
• ZO-1
Changes in the expression
and organization of
cytoskeleton components:
• Cytokeratin ↓
• Vimentin↑
• Stress fibers
• FSP1
• SMA
Changes in the expression and localization
of transcription factors and repressors:
• β-Catenin
• Snail1, 2
• Twist
• ZEB1, 2
• MRTF
• CBF-A/KAP-1
• Goosecoid
Changes in the expression of ECM
components, their synthetic machinery,
or their receptors:
• Collagens
• Fibronectin
• Prolyl hydroxylase
• HSP47
• DDR2
• Integrins
Figure 2 |Markers of epithelial–mesenchymal transition (EMT) and epithelial–myofibroblast transition. The indicators of type 2
(fibrogenic) EMT can be divided into four categories: changes in epithelial contacts, cell-associated extracellular matrix (ECM) components,
transcriptional regulators, and cytoskeleton. A variety of markers is listed in each category. A large set of in vitro data obtained in cultures of
tubular epithelial cells verifies that each of these changes can occur in kidney epithelial cells (showing the potentiality of the epithelium to
undergo EMT). Moreover, many of these changes have been documented in tissue samples from patients with kidney disease or in
animal models of fibrosis. The presence of multiple signs and the conclusive demonstration of the coexistence of epithelial and
mesenchymal hallmarks within the same cell are prerequisites to declare EMT. These alterations should initially occur within the histological
confines of the tubule. In later stages of fibrosis, the tubular borders cannot be well defined. CBF-A, CArG-box-binding factor-A; DDR2,
discoidin domain receptor-binding tyrosine kinase 2; FSP1, fibroblast-specific protein 1; HSP47, heat shock protein 47; KAP-1, KRAB-
associated protein-1; MRTF, myocardin-related transcription factor; SMA, a-smooth muscle actin; ZO-1; zonula occludens-1.
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encompass the overexpression of certain matrix proteins
(for example, fibronectin and collagen I), ECM-interacting
surface proteins, for example, a5 integrins55 or the collagen
receptor discoidin domain receptor-binding tyrosine kinase 2
(ref. 56), as well as enzymes and chaperones that are involved
in collagen synthesis (for example, heat shock protein 47 and
prolyl 4-hydroxylase).57 Changes in cytoskeletal elements
include the abovementioned downregulation of cytokeratin
and upregulation of vimentin along with the de novo
expression of FSP1 and occasionally SMA. Finally, in
conjunction with these responses, a multitude of transcrip-
tional activators or repressors has been shown to exhibit
characteristic changes during EMT. The best documented
examples are the translocation of the adherens junction
component b-catenin to the nucleus and the subsequent
activation of the T-cell factor/lymphoid enhancer factor-
induced transcription,30,32,58,59 which drives several mesen-
chymal genes; the expression of the zinc finger proteins
Snail1 and Snail2,60–63 the basic helix–loop–helix factor
Twist,64,65 and the zinc finger E-box-binding homeobox
proteins ZEB1 and ZEB2,36 which are strong repressors of
E-cadherin and several tight junction components66,67 and
can induce the expression of mesenchymal genes.68 Another
important event is the nuclear translocation of myocardin-
related transcription factor (MRTF),69–71 an actin cytoskele-
ton-regulated coactivator of serum response factor, the main
driver of the SMA promoter, and many other cytoskeletal
genes.72 As MRTF is translocated upon the disruption of the
intercellular contacts,69,70 this mechanism represents a direct
link between adherens junction integrity and the transcrip-
tional reprogramming of the cytoskeleton. In addition,
MRTF contributes to the downregulation of E-cadherin63
and the expression of collagen73 as well. Finally, recent
findings suggest that the complex of CArG-box-binding
factor-A and KRAB-associated protein-1 might act as a
master regulator of the EMT transcriptional program. This
complex binds to the cis element FTS1, which is present not
only in the promoter of FSP1, but in many of the
abovementioned transcriptional regulators as well, including
lymphoid enhancer factor 1, Snail, and Twist.74 Importantly,
CArG-box-binding factor-A overexpression is sufficient to
induce EMT, whereas inhibition of FSP1 expression is
sufficient to suppress it.75 These findings lend credence to
the notion that local FSP1 expression is an indicator and
accelerator of EMT.
Given this abundance of changes, the key question is: what
are the real criteria of the process, that is, which changes can
be taken as both necessary and sufficient requirements? It
seems reasonable to suggest that detection of at least one
feature within each of the four categories (contacts, ECM,
cytoskeletal components, and transcription factors) should
suffice. However, the detection of certain markers is by no
means necessary for the declaration of EMT. For example, the
expression of SMA should not be used as a criterion of EMT.
This conclusion is illustrated by the fact that even in vitro,
where all the above-described changes have been solidly
documented, various epithelial cells lines show differing
sensitivity to SMA expression.28–30,76 Moreover, even in
susceptible epithelial lines, transforming growth factor-b1
alone is often insufficient to induce SMA expression, and a
second hit, such as the disruption of the intercellular
contacts58,77 or the concomitant activation of specific
integrins,32,59 is a prerequisite. In any case, SMA expression
is a late event that follows the loss of E-cadherin29 and
increased ECM production, and it occurs only in a subset of
the transitioning epithelial cells.58,69 To distinguish this full-
blown form of EMT, our lab (AK) used the term
epithelial–MF transition or EMyT.78 We showed that EMyT
can be dissected to a fibrogenic and myogenic phase, which
can be distinguished by the underlying signaling.78 The first
phase requires the presence and activation of the transform-
ing growth factor-b effector Smad3, whereas the second
phase is inhibited by Smad3, because it suppresses the activity
of MRTF. Smad3 then gradually degrades, liberating the
myogenic program. Although Smad3 degradation has been
documented in vivo in a variety of fibrosis models78–80 (see
ref. 81), this process may be restricted to certain subsets of
epithelial cells or other MF progenitors. This view also raises
the possibility that epithelium-derived MFs (which may lack
Smad3) might be quite different from MFs generated by
other mechanisms, and they might not represent the most
aggressive ECM-producing MF variant. On the other hand,
reduced Smad3 (or in some cases Smad2.82) in tubular cells
may be an additional marker for the transitioning phenotype.
These observations are in perfect accord with those made in
the context of clinical disease and experimental models.
Thus, although SMA expression has been repeatedly demon-
strated in the epithelium during fibrosis (see the next
section), in most cases, only a small portion (2% or less) of
tubular epithelial cells has been found to stain positive for
SMA, and conversely, the majority of the SMAþ cells are not
localized within the tubular wall.16,57,83,84 Although in
principle, this might reflect that the majority of cells with
high SMA expression exhibit increased motility and have
already left the tubular epithelium, the much likelier
interpretation is that most SMAþ cells indeed do not derive
from the tubular epithelium. In accord with this, SMAþ
interstitial MFs did not seem to originate from in vivo Texas
red dextran-labeled tubular cells during UUO.85 In fact, this
conclusion is consistent with all lineage-tracing experiments,
as SMA has never been suggested as a sensitive marker of
tubular EMT. It detects the most robust form, but the process
does not have to go that far. Consequently, the absence of
widespread tubular SMA expression does not mean that there
is no tubular EMT. Moreover, it does not mean either that the
detectable tubular SMA expression is functionally insignif-
icant. This dramatic and possibly irreversible phenotypic
change can be an important contributor to the deterioration
of the tubular functions.
In conclusion, it would be worthwhile to combine the
lineage-tracing experiments with the concomitant assessment
of EMT in vivo, based on the four criteria discussed above.
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We propose that the loss of E-cadherin, a typical change in an
EMT-related transcription factor, and the expression of FSP1
are good candidates. The first two has not been assessed,
whereas FSP1 was found not to be expressed in the
epithelium upon UUO in the study by Humphreys et al.12
and Li et al.42 As opposed to the absence of SMA, this finding
is surprising and remains unexplained, given the large
number of studies that documented tubular FSP1 during
various forms of fibrogenesis (see next section).
Finally, it is worth addressing the overall relevance of the
in vitro studies. Their obvious limitation is that although
cultured cell lines and primary tubular cells can undoubtedly
undergo EMT in vitro, this fact cannot prove that tubular
cells do so in vivo. Nonetheless, these studies have been and
remain indispensable for defining the markers of EMT,
dissecting the responsible stimuli and, most importantly,
identifying the underlying complex signaling and transcrip-
tional pathways. The uncovered basic molecular mechanisms
remain relevant irrespective of the major source(s) of MFs in
a particular model or disease setting.
SNAPSHOTS: HOW TO CAPTURE THE ACTION
The real challenge in catching a cell in the act of EMT in vivo
is that it should remain sufficiently epithelial to be recognized
as such but should possess enough mesenchymal features so
that it can be clearly distinguished from the normal
epithelium. Owing to the transitional nature of the process,
any static image at a given time provides only a snapshot. In
addition, the steady-state number of the transitioning cells
does not tell us the total number of cells that have been (or
will be) undergoing transition. Ideally the process should be
followed in real time in labeled cells when both the changes in
cellular markers and the migration of the cells could be
monitored. With the increasing sophistication of long-term
intravital microscopy, such analysis might become available
in the future. However, currently most studies have been
based on the demonstration of coexistence of epithelial and
mesenchymal features. Epithelial origin can be substantiated
(although not quite proven) by cellular localization (that is,
when cells are situated luminally to the tubular basement
membrane, as long as the tubule remains an anatomically
distinguishable entity) by specific external labeling of the
tubular cells (for example, using lectins or the intravital
probe Texas red dextran that is endocytosed specifically by
tubular cells) or by detecting endogenous epithelial proteins
or mRNAs using immunohistochemisty or in situ hybridiza-
tion. The latter methods are also suitable to visualize
mesenchymal markers. Using such colabeling/localization
approaches, transitional tubular cells have been detected in a
large variety of experimentally induced fibrotic conditions,
including obstructive nephropathy,86–89 5/6 nephrectomy,83
diabetic nephropathy,90 experimental glomerulonephritis,90
antitubular basement membrane nephritis,18 nephrotoxic
serum nephritis,39 allograft nephropathy,91 human immuno-
deficiency virus-associated nephropathy,92 polycystic kidney
disease,84 and others. Moreover, similar observations were
made in human biopsy samples obtained from patients with
pauci-immune crescentic glomerulonephritis,93 lupus ne-
phritis,94 minimal change disease,95 immunoglobulin A95,96,
chronic allograft,97–99 and diabetic nephropathies.100 In a
thorough study, Rastaldi et al.57 investigated 133 renal
biopsies from a cohort of patients with minimal change
disease, membranous nephropathy, immunoglobulin A
glomerulonephritis, focal segmental glomerulosclerosis,
membranoproliferative glomerulonephritis, lupus nephritis,
and diabetic nephrosclerosis. They used a whole array of
markers, comprised of proliferation indicators; the expres-
sion of vimentin, SMA, and prolyl hydroxylase; the loss of
zonula occludens-1 and cytokeratin; as well as the detection
of collagen I and III protein and mRNA. They determined the
number of tubular cells/high-power field that exhibited
alterations in these markers and found an increase in each
of the investigated EMT indicators compared with normal
controls. The rarest of the tubular alterations was the
expression of SMA. Importantly, they observed mesenchymal
and ECM antigens, together with the loss of epithelial
properties in well preserved tubular structures without
basement membrane disruption, and were able to detect
tubular cells that were positive for both cytokeratin and
mesenchymal markers. Moreover, each marker showed
significant correlation with clinical or histological parameters
(for example, serum creatinine or the level of interstitial
fibrosis). Taken together, a large number of studies lend firm
support to the concept that in a variety of human kidney
diseases, the injured epithelium shows several signs of
epithelial plasticity, which are consistent with EMT. The
pathogenic role of EMT in kidney fibrosis is further
supported by recent findings, which indicate that interven-
tions targeted against the EMT program exert antifibrotic
effects. Members of the miR-200 family of microRNAs have
been shown to mitigate EMT by inhibiting the expression of
ZEB1 and ZEB2, which in turn are strong suppressors of the
E-cadherin gene. Importantly, administration of miR-200b
precursor suppressed the UUO-induced increase in ZEB
proteins and reduced the ensuing fibrosis.36
In summary, despite the limitations of the snapshot
approach as discussed above, substantial evidence supports
the claim that EMT does occur during clinical kidney disease.
Although the majority of MFs may indeed originate from
other sources, all viable models of the pathogenesis of kidney
fibrosis should account for the dramatic changes that occur
in the tubular epithelium and should explain how these
alterations contribute to the progression of fibrosis.
FATE MAPPING AND LINEAGE TRACING
The ability to permanently tag cells in vivo has provided
additional insights and raised further questions regarding the
process of EMT. Under the control of epithelial-specific gene
promoters, expression of Cre recombinase in the renal
tubular cells results in genomic recombination between loxP
sites, with subsequent production of a reporter protein that
marks the epithelial lineage with a blue, green, or red
46 Kidney International (2011) 80, 41–50
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color.101–103 The assumption is that regardless of final
phenotype if a cell was ever an epithelial cell it will carry
the color marker. In theory, epithelial cells that have
undergone EMT should be tagged and express the reporter
gene as well as markers of fibroblast/MF lineage discussed
above. This removes the need to identify or guess at the
origin of the cell and it is not necessary to find an
intermediate phenotype or capture a cell in the tubular
lumen that is undergoing transition. A number of studies
have been performed using this technique with varying and
sometimes contrasting results (see Table 1). The original
study of Neilson group16 used the gamma GT promoter to
drive Cre expression and a RosaR26 lacZ reporter mouse
strain that results in tagging the proximal tubular epithelial
cells. Following UUO, the authors clearly showed cells that
expressed FSP1 and were positive for the lacZ gene product
b-galactosidase, as visualized by an antibody against the
enzyme (Figure 3). In more recent studies, Humphreys
et al.12 used the Six2 Cre mouse line that tags all epithelial
progenitors and subsequent epithelial derivatives that include
epithelial cells from proximal down to the distal tubule. They
also used a HoxB7 Cre mouse line that labels the collecting
duct epithelium. They used a fluorescent red tag for epithelial
cells and were unable to find a single cell that coexpressed the
red lineage marker and FSP1, suggesting that not a single
epithelial cell underwent EMT (Figure 3). Similar results were
obtained when they used the same Cre driver with the Rosa26
lacZ reporter and visualized b-galactosidase through its
enzymatic activity. Conversely, tagging cells from the Foxd1
lineage, which gives rise to stromal derivatives that likely
include pericytes and peritubular fibroblasts/MFs, showed
that these cells can contribute to the FSP1þ population in
fibrotic rodent models. Why are the results so different?
Although it is difficult to determine without performing
head-to-head experiments, there are several issues to
consider. Although very informative, it must be remembered
that even the most robust Cre excisors may vary in their
ability to tag all cells that express Cre; even within a single
mouse litter, Cre expression and efficiency of excision may
vary raising the possibility that sub-populations of the
Tubular epithelium
UUO
STOP LacZ LacZ
LacZ
Lox P Lox P Lox P Lox P
GFP–Cre
RFP
RFP
+
Interstitial
cells
X X
γGT
promoter Cre
Rosa26
promoter
Rosa26
promoter
Iwano et al. Humphreys et al.
Anti-β-gal (red)
Anti-FSP1 (green)
Yellow = FSP1 in the epithelium
EMT
Tubular epithelium
UUO
Red = no FSP1 or
SMA, no EMT
Anti-FSP1 or
Anti-SMA (green)
Six2
promoter
CMV/β-actin
promoter
CMV/β-actin
promoter
Figure 3 | Fate-mapping strategies to assess epithelial–mesenchymal transition (EMT) (or epithelial–myofibroblast transition)
during experimental tissue fibrosis. Transgenic mice with genetically tagged epithelium represent a new and valuable tool to investigate
the contribution of EMT to fibrogenesis. To label tubular cells, Iwano et al.16 used the g-glutamyl transferase promoter coupled to Cre
recombinase, which in turn activated the transcription of the lacZ gene (b-galactosidase) by removing a floxed stop codon from the
ubiquitous Rosa26 promoter. The b-galactosidase expression (epithelial origin) was visualized by an antibody against the enzyme. Upon
unilateral ureteral obstruction (UUO), they found b-galactosidase-positive cells that costained for fibroblast-specific protein 1 (FSP1; and to a
much lesser extent for a-smooth muscle actin (SMA)), indicting EMT. Humphreys et al.12 used the Six2 promoter to drive Cre, which induced
the expression of red fluorescent protein (RFP) through the activation of the cytomegalovirus (CMV)-enhanced b-actin promoter. They
induced UUO in these transgenic mice, and found that no red (epithelium derived) cells stained positive for FSP1 or SMA, suggesting that
EMT did not take place. SMA or FSP1 positivity (green) was detected in interstitial cells. They got similar results using the same Cre
driver in combination with the Rosa26 lazcZ reporter using an enzymatic assay to detect in situ b-galactosidase activity. GFP, green
fluorescent protein.
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epithelium may remain ‘untagged’.104 In turn, reporter genes,
chosen for their ubiquitous expression, may switch ‘off ’ as
cells differentiate or transdifferentiate. Although a lineage tag
assumes that the marker is permanent, it depends upon
continued transcription of the reporter gene that might
become silenced. The Duffield group performed control
experiments showing that in vitro (as opposed to in vivo)
epithelial (that is, red) cells undergo transformation, yet they
tend to keep the label (although the labeling appeared rather
weak and uneven among SMA expressors). Nonetheless, this
can be interpreted in two ways: SMA expression in the
epithelium occurs only in vitro or the transforming epithelial
cells lose the lineage tag predominantly in vivo. Further, when
multiple transgenes are required as in these tagging
experiments, mixed mouse strain backgrounds are often
unavoidable, adding an additional variable. Finally, it is not
possible to conclude that different reporters behave in a
similar manner. Enzymatic reactions as required for the
b-galactosidase gene in the RosaR26 line versus fluorescence
in the Z/RED or Z/EG lines exhibit differences; single-cell
resolution is variable, depending on the availability of robust
antibodies for costaining. Cytoplasmic b-galactosidase ex-
pression as revealed by enzymatic conversion is very sensitive
but tends to bleed and diffuse in tissues with higher
background noise, making identification of individual cell
populations within the interstitium difficult. It is noteworthy
that studies supporting tubular EMT used antibody-based
detection of b-galactosidase, whereas those against it used the
X-gal reaction. Side-by-side comparison of the results
obtained with these methods in the same system may be
warranted.
There are ways to overcome some of these variables; one can
design the ‘best’ experiment using reporters that can be
detected with high-resolution antibodies at the single-cell level
(green fluorescent protein is an excellent one), or isolating
‘fibroblast cells’ from the organ and looking for evidence of
genomic rearrangement by PCR without the need to detect
expression of the reporter (for example, see ref. 105). Thus,
although lineage tracing is a powerful technique, it is not
necessarily definitive, and investigators should recognize that
the results are not always as black and white as they appear.
CONCLUDING REMARKS
The debate is on, and it is an exciting and intellectually
productive one. In fact there are two sets of controversies.
The first is intrinsic: what is the reason for the discrepancies
between the studies using different fate-mapping methods in
the same fibrosis model, UUO? Here, the resolution may be
of technical nature, as discussed above. The second is an
extrinsic one: why is it that the recent lineage-tracing studies
fail to see any sign of EMT, whereas a compelling cohort of
histological observations from human diseases does show
signs of the process? Let us suppose that both observations
are correct and valid. If so, is it possible that the chronic,
more slowly-developing disease processes, in which cycles of
epithelial injury and healing can alternate, are more prone to
mobilize the EMT program than the rather acute and robust
models (UUO, acute ischemic injury)? Can it be a question of
the type and timing (kinetics) of the disease process? Could it
be that in certain pathologies, the pericytes are the prime
‘fibrotic responders’, whereas in others, tubular EMT might
have a more significant role? To decide whether there is a
discrepancy at all, fate-mapping studies should also be
performed in the context of more chronic disease models.
Another intriguing question arises from the experiments of
Humphreys et al.12 who showed that RFP-tagged (that is,
epithelial) cells do undergo EMT and even EMyT when
challenged in vitro. So why don’t they do so in vivo? What is
the missing triggering factor, or conversely, what anti-EMT
factors are present to prevent this process? Do these factors
change in time? Understanding of this difference may be
highly informative. Furthermore, if pericytes are the culprit,
how is the myogenic program (SMA production) mobilized
in them? Do they use—as one would hypothesize—similar
transcriptional reprogramming mechanisms (for example,
contact-dependent MRTF translocation, Snail/ZEB/Twist acti-
vation, CArG-box-binding factor-A/KRAB-associated protein-
1-mediated responses, and so on) as those described in the
epithelium? What is the role of the epithelium in the activation
of the other fibrogenic and myogenic cells, that is, what is the
nature of epithelial–mesenchymal interactions?
With so many questions, one point remains certain:
irrespective of the final outcome, the concept of fibrogenic
EMT has proved to be vastly fruitful; it has opened and
continues to open new avenues, as this very debate
exemplifies it. It may turn out—as was often the case in
the history of science—that both views hold a good chunk of
the truth. The point is to keep up the inspiring discussion
and the inquiry. Finally, it is important that while both sides
strive to understand and conquer kidney fibrosis, the debate
itself should not cause any scarring.
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